Home
World Journal of Advanced Research and Reviews
International Journal with High Impact Factor for fast publication of Research and Review articles

Main navigation

  • Home
    • Journal Information
    • Editorial Board Members
    • Reviewer Panel
    • Abstracting and Indexing
    • Journal Policies
    • Our CrossMark Policy
    • Publication Ethics
    • Issue in Progress
    • Current Issue
    • Past Issues
    • Instructions for Authors
    • Article processing fee
    • Track Manuscript Status
    • Get Publication Certificate
    • Join Editorial Board
    • Join Reviewer Panel
  • Contact us
  • Downloads

eISSN: 2581-9615 || CODEN: WJARAI || Impact Factor 8.2 ||  CrossRef DOI

Research and review articles are invited for publication in June 2026 (Volume 30, Issue 3) Submit manuscript

Vitiligo induced by immune checkpoint inhibitors in metastatic melanoma: A case report and review of the literature

Breadcrumb

  • Home
  • Vitiligo induced by immune checkpoint inhibitors in metastatic melanoma: A case report and review of the literature

A. Debbagh 1, *, L. Alaoui 2 and R. Tanz 3

1 Department of Medical Oncology, Military Hospital Instruction Mohamed V, Rabat.
2 Department of oncology, Military Hospital Instruction Mohamed V, Rabat.
3 Medical Oncology Service, Military Hospital Instruction Mohamed V, Rabat.
 

Case Report

World Journal of Advanced Research and Reviews, 2026, 30(03), 249-252

Article DOI: 10.30574/wjarr.2026.30.3.1570

DOI url: https://doi.org/10.30574/wjarr.2026.30.3.1570

Received on 23 April 2026; revised on 01 June 2026; accepted on 03 June 2026

Background: Immune checkpoint inhibitors (ICIs) have revolutionized metastatic melanoma treatment but cause immune-related adverse events (irAEs), particularly dermatologic toxicities. Vitiligo is a distinctive cutaneous irAE occurring predominantly in melanoma patients.
Objective: To report a case of ICI-induced vitiligo and discuss its pathophysiology, management, and prognostic significance.
Case Presentation: A 54-year-old man with stage IV melanoma received pembrolizumab. After 24 weeks, progressive depigmented macules appeared on the face, hands, and trunk, accentuating with continued treatment. Biopsy confirmed vitiligo. Pembrolizumab continued with topical corticosteroids. At 6 months, partial tumor response with persistent vitiligo.
Conclusion: Vitiligo is a benign irAE correlating with favorable antitumor response. ICI continuation is recommended. Multidisciplinary management optimizes outcomes.
 

Immune checkpoint inhibitors; Vitiligo; Cutaneous toxicity; Immunotherapy; Melanoma

https://wjarr.com/sites/default/files/fulltext_pdf/WJARR-2026-1570.pdf

Preview Article PDF

A. Debbagh, L. Alaoui and R. Tanz. Vitiligo induced by immune checkpoint inhibitors in metastatic melanoma: A case report and review of the literature. World Journal of Advanced Research and Reviews, 2026, 30(03), 249-252. Article DOI: https://doi.org/10.30574/wjarr.2026.30.3.1570

Copyright © Author(s). All rights reserved. This article is published under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, sharing, adaptation, distribution, and reproduction in any medium or format, as long as appropriate credit is given to the original author(s) and source, a link to the license is provided, and any changes made are indicated.

All statements, opinions, and data contained in this publication are solely those of the individual author(s) and contributor(s). The journal, editors, reviewers, and publisher disclaim any responsibility or liability for the content, including accuracy, completeness, or any consequences arising from its use.

Get Certificates

Get Publication Certificate

Download LoA

Check Corssref DOI details

Issue details

Issue Cover Page

Editorial Board

Table of content

Copyright © 2026 World Journal of Advanced Research and Reviews - All rights reserved

Developed & Designed by VS Infosolution